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There are hundreds of different
studies that have tried to link genetics
and predispositions to addiction.
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Abstract
Prescription pain-relievers can be powerfully effective agents in
the treatment of moderate to severe pain; however, these
drugs are also strongly associated with drug abuse and addiction. In the brain, opioid analgesics bind to various receptors in
the mesocorticolimbic dopaminergic pathways, which play a
role in reward. Several specific single nucleotide polymorphisms (SNPs) have been identified as potential genetic factors
that increase an individual's risk for addiction; however, confounding studies and lack of large trials prohibit definitive conclusions from being drawn. As a result of genetic testing, federal and state laws have been enacted to protect individuals from discriminations. As more definitive evidence becomes apparent,
a large impact on pharmacy practice is expected.

Drug addiction is a complex disease
that is difficult to treat due to the
multifaceted interaction of
environmental1 social1 psychological
and genetic factors.

Introduction
Prescription pain-relievers are essential pharmacologic tools in the treatment of moderate to severe pain; however, due to their
euphoric potential, these drugs are strongly associated with misuse, which can lead to abusive behaviors. Over time, there has
1
been a dramatic increase in the use and abuse of opioid analgesics. As physicians have resorted to treating chronic pain with more
12
powerful analgesics, an exponential growth in the domestic sale of opioids has been observed . - Currently, many researchers are
studying variations in DNA that increase a person's risk for developing opioid addiction. Theoretically, by understanding those mutations in the genome responsible for an increased risk for addiction, physicians will be able to make more appropriate decisions
when prescribing a drug and dosage regimen to treat chronic pain while minimizing the risk of addiction. When considering pharmacogenomic-based dosing regimens, it is important to consider environmental and psychosocial risk factors as well. In response
to genetic testing to identify disease-related causation and predisposition, a growing number of federal and state laws have been
enacted to protect patients from insurance and employment discrimination that might exclude or otherwise penalize patients on
the basis of their specific genetic profiles.
Pathology of Opioid Dependence
Opioids, such as heroin, oxycodone and morphine-like substances, exert their action by binding to a number of receptors throughout the body. The most common receptors include the µ,
and K opioid receptors. Though they are located throughout the central nervous system {CNS), there is a high concentration of these receptors in the nucleus accumbens (NAc}, ventral tegmental area
(VTA), locus cerulus (LC), and prefrontal cortex (PFC). These individual brain components are incorporated in the mesocorti3
colimibic dopaminergic pathway, which plays an important role in reward, laughter, pleasure, fear and addiction.

o,

According to Goodman & Gilman's, the Figure 1.
mesocorticolimbic dopaminergic pathway
originates in the VTA and projects into the
G:lUlamata
ini:iut
NAc and forebrain. Dopamine released from
the VTA binds to post-synaptic dopamine
(D2) receptors in the NAc on GABAergic neurons, producing an inhibitory response. The
stimuli that cause the release of dopamine
to the NAc, thereby allowing the catecholamine neurotransmitter to occupy the D2-like
receptors, presumably elicits a positive reward and causes the user to experience a
euphoric "high." This high is experienced
through stimulation by natural endogenous
substances or exogenous substances, like
heroin or morphine. One way to activate this
reward center is via the opioid receptors. It
is hypothesized that the receptors increase
VTA
the amount of dopamine stimulating the
receptors in the NAc and/or directly stimu- - - - - - - - - 3
lating the NAc, resulting in a "high" (Figure 1).
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Drug addiction is a complex disease that is difficult to treat due to the multifaceted interaction of environmental, social, psychological and genetic factors. Currently, pharmacogenomics is being utilized to examine patient populations' DNA and SNPs, which
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have been associated with an increased risk for an individual to develop addiction. More specifically, research efforts are being
concentrated into identifying SNPs in genes that code for the µ-opioid receptor and its associated signal transduction mechanisms.
SNPs in Genetic Code

Researchers are exploring potential genetic predispositions to
drug addiction. A genetic predisposition to addiction does not
mean an individual will inescapably become addicted to a medication. Genetic variations in DNA may, however, predispose the
individual to addiction, increasing their relative risk. Relative risk is
defined as the measure of risk of an event in one group compared
to the same event in another group. For example, people who are
not genetically predisposed to addiction can still become addicted. Likewise, people who are genetically predisposed will not necessarily become addicted. Current research has discovered
SNPs associated with the mesocorticolimbic pathway and evidence suggests that some of these SNPs may be linked to opioid addiction.

Genetic variations in DNA may,
however, predispose the individual to
addiction, increasing their relative
risk.

A118G
One of the more widely studied SNPs thought to be involved in opioid addiction is known as rs1799971. This SNP is also referred to
as A118G located on exon 1 of the gene OPRMl {Opioid Receptor µ 1), which can be found on chromosome 6. OPRMl codes for
the µopioid receptor, which is responsible for binding endogenous and exogenous ligands. Binding of these agonist ligands results
in the activation of the mesocorticolimbic pathway to produce sensations of pleasure in the brain. This SNP results in a nonsynonymous substitution of asparagine for aspartic acid on the µ-opioid receptor, resulting in altered function (Figure 2). 4 With
this particular SNP individuals will be either homozygous AA,
Figure 2.
homozygous GG or heterozygous AG. In most populations
the AA is the wild type, or the most frequently seen genotype. Studies investigating this SN P have yielded variable
results, making it difficult to determine the precise impact
Po11Uan 118
on drug addiction.
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with methadone and 39 control subjects who had no history
of drug or alcohol abuse. This study compared the frequenCoding Changes
DNA
DNA Sequences
cies of the A118G polymorphism between the two groups
and found no significant increase in the occurrence of the
A118G SNP within the heroin addiction group. Although there was no relationship between the frequency of A118G occurrence
and addiction, the researchers did find the SNP was associated with a threefold increase in binding affinity to ~-endorphin. The SNP
resulted in physiological changes in the brain, leading researchers to think that SNPs along with other factors could potentially in5
crease a patient's risk of addiction.
~~~~~~~~~

Another study looked at the A118G polymorphism and its association with opioid addiction, specifically to heroin. The study examined postmortem individuals. Sixty-five patients were divided into two groups; 26 non-heroin users in a control group and 39 heroin addicts. Researchers found a greater frequency of the heterozygous AG genotype in the heroin-addicted individuals {25.6 per2
cent) compared to the control group (3.8 percent). This data provided a X =6.153 and p=0.013, which showed a significant difference between the two groups in the prevalence of the AG genotype. The same study was then preformed with 53 new subjects,
splitting subjects into a control group (n=14) and a heroin addiction group (n=39). The second study also revealed a higher fre2
quency of AG genotype in the heroin addiction group which provided a X =4.741 and p=0.03. This study also analyzed the postmortem brains of these subjects. In individuals with the AG genotype, researchers found an altered expression of the µ-opioid receptor
and molecular differences that could potentially provide a mechanism for opioid addiction . 6 This suggests that A118G could play a
role in addiction. Due to the confounding results, a clear conclusion cannot be drawn.
In 2012, researchers uncovered a link between the A118G polymorphism and heroin addiction. The first study compared 130
heroin addicts to 200 non-addicted subjects in an Indian population. The frequencies of the AA, GG and AG genotypes in the
addicts were 54 percent, 41 percent and 5 percent, and in the
control group, the frequencies were 68.5 percent, 27.5 percent
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In 2012, researchers uncovered a link
between the A118G polymorphism and
heroin addiction.

and 4 percent. These genotype frequencies demonstrated a significant difference between the two groups as demonstrated by a
X2 =7.268 and p=0.0264. Overall, it was shown the G allele was significantly more prevalent in the heroin addiction group as evidenced by an odds ratio (OR)=l.609 (1.102-2.348). As with the previous study, the AG genotype had the highest frequency in the
addiction group and was associated with the greatest risk for addiction as demonstrated through the OR=l.886 (1.173-3.032) com7
pared to the wild type AA genotype.
Based on the three studies previously mentioned, it appears that the A118G may be implicated in opioid addiction, specifically if
the individual is heterozygous AG. Drakenberg et al. and Deepak et al. also found an increased association between the A118G SNP
7
and opioid addiction. 6' 7 Furthermore, there is evidence of physiologic changes that are associated with these SNPs. 6' The A118G
SNP could potentially be involved in opioid addiction, but more research is required. New SNPs are being discovered each day, and
as a result some of the newer discoveries may provide a greater link to addiction than A118G.

CREBBP
One recent study provides evidence that a SNP in the cAMP response element binding protein (CREB) may be implicated in opioid
addiction. Researchers identified SNP rs3025684, coding for CREB binding protein (CREBBP) intron 21 on chromosome 16. The
study compared 131 heroin addicts with_150 individuals in India who had no history of alcohol or drug abuse to act as a control
group. 8 With respect to this SNP, individuals possess either the homozygous GG, homozygous AA, or the heterozygous AG. The
most common allele found was the G allele, with the A allele being less common. The dominant genotype identified within both
study groups was homozygous GG, which is generally the most common among most
9
populations. The frequencies were given for the GG, AA and AG genotypes for the
opioid dependent group (74 percent, 3 percent, and 23 percent) and the control group
(93.3 percent, 1.3 percent and 5.3 percent), respectively. The study showed significant
2
differences (X =20.28, p<0.0001) in the subjects' genotypes between the control and
the opioid addicts. There was an association between the A allele and opioid addiction.
When comparing the opioid addicted group to the control group for the presence of
the A allele, there was an OR= 4.11 (2.09-8.05). The AG genotype appeared to have the
greatest distribution in the opioid dependent groups compared to the control group,
giving an odds ratio of 5.32 (2.32-12.10). This study concluded that this SNP in CREB
might be implicated in the development of opioid addiction. The effect on activity of
the intron region in DNA is not completely understood. The researchers did conclude,
however, that individuals with the rs3025684 SNP might potentially be at a higher risk
8
for developing addiction.
There are hundreds of different studies that have tried to link genetics and predispositions to addiction. Researchers have not yet
been able to definitively link the two at this point due to a lack of conclusive evidence available from these studies. In addition,
there is even less evidence available to mechanistically explain how these SNPs could predispose an individual to addiction. Individual SNPs may predispose an individual to addiction, but like many other diseases there are many other factors that play a role. One
aspect that weakened many of the studies reviewed was the design - while evidence is promising that certain SNPs may play a role
in addiction, a lack of large studies that incorporate greater sample sizes and
multiple ethnic groups limited the implications of the study results.
If a SNP is identified in a gene, which is linked to an increased risk of developing addiction, individuals may be concerned about the implications. Current
studies suggest certain SNPs may cause a higher relative risk, but because
most study designs have multiple limitations, definitive conclusions cannot be
drawn. While most studies concluded that multiple SNPs might contribute to
the overall genetic relative risk to developing addiction, this issue has yet to
be studied in clinical trials. Similarly, most studies did not incorporate environmental and psychosocial factors into their study design, which are additional, major contributors to drug addiction. For individuals still concerned - ;;;....- -.;;"--..-...0..--1-...-......
about negative implications, federal and state laws are already in place to protect against discrimination in employment and insurance ratings.
Federal and State Law

The Genetic Information Nondiscrimination Act (GINA) of 2008 was signed into Law by President Bush on May 21, 2008. 10 The law
11
took effect on November 21, 2009. GINA has two major components; Title 1 of the law deals with issues pertaining to health in11
surance, and the second title addresses employment issues. GINA protects the genetic information of not only individuals, but
extends protection to family members of the individual, and covers any information pertaining to the manifestation of disease for
Genetic Predispositions to Opioid Addiction, Legislative Action and Implications to Pharmacy Practice I July 2012
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both the individual and family. This includes information obtained during participation in clinical research. Genetic information
protection includes any analysis of DNA, RNA, chromosomes, proteins or metabolites that are used to detect genotypes, mutations, SNPs or chromosomal changes. Testing for proteins or metabolites that do not detect genotypes, mutations or chromosoma I
11
changes are not protected under this act .
Title 2 states that employers may not use genetic information to
make decisions about hiring, firing, compensation, terms, conditions or privileges of employment. Moreover, genetic information may not be used to limit, segregate or classify the employee
in any way that would deprive the employee of opportunities
that he/she may have had otherwise. Title 2 also puts limitations
on how an employer may obtain information. Employers cannot
request, require or purchase genetic information, with several
exceptions. Examples of these exceptions include: written consent of the employee, government-required genetic monitoring
or a job with the potential for DNA contamination (forensic lab
technician), etc. The regulations established by Title 2 apply to training programs as well as to labor organizations. Genetic information held by any of these organizations is to be handled much like protected personal medical information. It is legal for an employer to require a test to see if an employee has drugs in their body, but it is illegal to require testing of employees to determine
their predispositions to addiction. It is not to be released, like medical information, with several exceptions, including court order
or written approval of the employee. GINA also outlines the formation of a committee to review the law and make recommendations for updates and changes after six years. This committee will consist of eight members, appointed by various government officials.

Title 2 states that employers may not
use genetic information to make decisions about hiring, firing, compensation, terms conditions or privileges of
employment.

~~~~~~~~~~~~~~~~~~~~~~~--'

Title 1 covers health insurance rules and regulations. Much like Title 2, GINA prevents a group health plan from requiring an individual or family member to undergo genetic testing. The plan can, however, request a patient go under genetic testing for research
as long as it is clearly stated that compliance is strictly voluntary. The insurer may not request, require or purchase genetic information for underwriting purposes or prior to an individual's enrollment in a plan. Information that is obtained "by accident" is, of
course, not in violation of GINA. Genetic information cannot be treated as typical, routine health information such as height,
weight, age or medical conditions. Genetic information that is legally obtained cannot be used to deny an individual coverage, impose exclusions for "pre-existing conditions" or require an individual to pay a higher premium. The patient must display the phenotype of the disease to impose such penalties. "GINA also amends Title XVIII of the Social Security Act to prohibit the use of genetic
information to form discriminatory policies for medical supplies." Definitions of genetic information, genetic tests and services are
12
the same as those outlined in Title 2. Family is defined as a dependent or relative out to fourth degree.
The Secretary of Labor is authorized by GINA to impose a penalty to health insurers in the group market that violate the law, or to
issue a waiver if it is determined that the failure was reasonable and not due to negligence. The bill further extends these rules and
regulations to protect individuals buying private health insurance. The Secretary of Health and Human Services retains the right to
12
discipline any health insurer in the individual market.
According to the National Conference of State Legislatures, each state has its own laws concerning genetic testing in addition to
13
GINA. Most states give their own definition of genetic testing, genetic information, and have their own disclosure policies. There
is a high degree of variability among state legislation regarding protection of genetic information; for example, some states extend
GINA protection to disability insurance, while others do not regulate genetic information as it pertains to life, long-term care and
15 16
disability insurances. ' Research in pharmacogenomics is advancing quickly; as our understanding of genetics continues to progress, the laws enacted to protect genetic information must follow.
Implications to Pharmacy Practice

Hypothetically, what if a discovery were made that indicated a certain genotype of a given SNP was clearly related to an increased
likelihood of becoming addicted? Would that change how physicians prescribe narcotics to patients? What would happen if a physician prescribed a narcotic to a patient who was predisposed to addiction, and both the pharmacist and physician had the genetic
information on hand, but failed to recognize the predisposition? What if that patient becomes addicted and the doctor or the pharmacist is held liable? These points address many concerns of how misuse of genetic information could occur.
Ultimately, what does the search for a genetic link or predisposition to addiction mean for the practice of pharmacy? As more concrete relationships are established, opioid prescribing patterns may change . With regards to narcotics, pharmacists may have the
ability to check gene-drug interactions if an associated predisposition to addiction can be identified. The pharmacist could be responsible for identifying high-risk individuals and consulting with the physician about changing pain management regimens in order
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to avoid the potential of addiction in those patients considered high risk. The obvious benefit is our ability to prevent patients from
receiving a medication if they have been identified as being at an increased risk of becoming addicted, but this may result in patients being unable to receive adequate analgesia or perhaps require some other alteration in treatment protocols.
As is the case with any genetic information, misuse and abuse are major public concerns. Could information about addiction be
used to prevent you from obtaining a job in the medical profession? Some would argue it makes sense to keep those who are predisposed to drug abuse away from drugs. GINA clearly states that employers cannot use this information, but what about schools?
Will medical professions screen applicants and reject entry into professional programs based upon genetic predispositions for addiction?
The law involving pharmacogenomics relative to patient care is very limited. The laws that are in place primarily protect individuals
from discrimination from insurance and employment opportunities. The primary law concerning the practice of pharmacogenomics
in the pharmacy setting is the Omnibus Reconciliation Act of 1990 (OBRA 90). According to this law, pharmacists must maintain
17
proper patient records, perform prospective drug use reviews (Pro-DUR) and counsel patients. However, OBRA 90 does not
specifically address patients' genetic information. Much like Social Security Act and the Health Insurance and Portability and
Accountability Act (HIPPA) were amended in GINA, the genetic information component of health care needs to be addressed and
amended in OBRA 90.
Conclusion
As technology and understanding of the human genome continue to advance, the role of genetics will become more evident. The
identification of SNPs, predisposing a person to addiction, may be revealed. It is important to understand the basic science of drug
addiction, and how genetic variants may drastically impact pharmacokinetic and pharmacodynamic processes, leading to altered
responses. This is the fundamental idea in attempting to identify any genetic predispositions to drug addiction. Laws have been
enacted to protect the individuals from the misuse of their genetic information. Advances in the field of pharmacogenomics will
require adaption by both the judicial system and medical professionals.
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